Overview of the fluoroquinolone antibiotics.
The fluoroquinolones represent an important advance in antimicrobial therapy. Commercially available products in the United States now include norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin. Although they share a common mechanism of action, they differ significantly in their antimicrobial spectrum of activity, their pharmacokinetic characteristics, and, to a lesser degree, their safety profiles. These compounds are generally highly effective against aerobic gram-negative and many gram-positive isolates; their activity is more limited against anaerobic bacteria. Quinolone-resistant bacteria have been isolated, but most do not appear to pose a clinically significant problem at this time. The agents are effective in the treatment of a wide range of infections. Although some, such as ciprofloxacin and enoxacin, have been associated with clinically significant interactions with theophylline derivatives, others such as ofloxacin and lomefloxacin appear to have a limited propensity for such interactions.
Clinical Pharmacy Programs, Premier Hospitals Alliance, Inc., Westchester Illinois 60154-5735.
P M
PM
Just
D000890:Anti-Infective Agents / Q000009:adverse effects / Q000494:pharmacology; D001424:Bacterial Infections / Q000188:drug therapy; D002939:Ciprofloxacin / Q000494:pharmacology; D004347:Drug Interactions; D004352:Drug Resistance, Microbial; D015365:Enoxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D006088:Gram-Negative Aerobic Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D009643:Norfloxacin / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D015365:Enoxacin; D002939:Ciprofloxacin; D015242:Ofloxacin; C053091:lomefloxacin; D009643:Norfloxacin